MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Vaccine
Institutions: Saint Louis University, Emmes (United States)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4210529157
